| Literature DB >> 24053550 |
Jayanth Sridhar1, Harry W Flynn, Ajay E Kuriyan, Darlene Miller, Thomas Albini.
Abstract
BACKGROUND: The purpose of the current study was to analyze risk factors, clinical features, and treatment outcomes in patients with endogenous fungal endophthalmitis with yeast and mold infections. For this retrospective consecutive case series, microbiologic and clinical records were reviewed to identify all patients with intraocular culture-proven endogenous fungal endophthalmitis treated at a single institution between January 1, 1990 and December 31, 2011.Entities:
Year: 2013 PMID: 24053550 PMCID: PMC3848556 DOI: 10.1186/1869-5760-3-60
Source DB: PubMed Journal: J Ophthalmic Inflamm Infect ISSN: 1869-5760
Microbiology of endogenous fungal endophthalmitis
| Yeast (39) | |
| | 34 |
| | 3 |
| | 2 |
| Mold (14) | |
| | 7 |
| | 2 |
| | 2 |
| | 1 |
| | 1 |
| | 1 |
Figure 1Endogenous fungal endophthalmitis caused by yeast. A 34-year-old HIV-positive woman presented with 20/25 vision in the left eye. Fundoscopic examination demonstrated a focal yellow retinal lesion inferotemporal to the optic nerve in the left eye. The patient underwent vitreous paracentesis in the left eye with cultures growing Candida albicans. The patient received three intravitreal injections of amphotericin B. Visual acuity on final follow-up was 20/25.
Figure 2Endogenous fungal endophthalmitis caused by mold. A 39-year-old man with history of IV drug use presented with redness and HM vision in the right eye. Fundus examination revealed vitritis and retinitis centered in the macula (above left). The patient underwent pars plana vitrectomy with injection of intravitreal amphotericin B. Pars plana vitrectomy specimen was positive for Aspergillus glaucus. Visual acuity on final follow-up was 4/200 (above right).
Systemic risk factors for endogenous fungal endophthalmitis
| Recent hospitalization | 26/39 (66.7%) | 9/14 (64.3%) | 0.872 |
| Recent surgery | 12/39 (30.8%) | 4/14 (28.6%) | 0.878 |
| Any immunocompromise | 20/39 (51.3%) | 9/14 (64.3%) | 0.402 |
| Iatrogenic | 3/39 (7.7%) | 8/14 (57.1%) | |
| Diabetes mellitus | 7/39 (17.9%) | 4/14 (28.6%) | 0.589 |
| Cancer | 9/39 (23.1%) | 3/14 (21.4%) | 0.899 |
| HIV | 3/39 (7.7%) | 0/14 (0.0%) | 0.285 |
| Any IV/IVDU/catheter/HD | 16/39 (41.0%) | 10/14 (71.4%) | |
| IVDU | 6/39 (15.4%) | 4/14 (28.6%) | 0.279 |
| Indwelling catheter | 3/39 (7.7%) | 0/14 (0.0%) | 0.285 |
| History of transplant | 1/39 (2.6%) | 5/14 (35.7%) | |
| Positive systemic culturea | 10/39 (25.6%) | 2/14 (14.3%) | 0.384 |
HIV, human immunodeficiency virus; IV, intravenous line; IVDU, intravenous drug use; HD, hemodialysis port; Pearson chi-square test used for statistical analysis. a Positive systemic cultures for yeast included blood (7), urine (2), and cerebrospinal fluid (1). Positive systemic cultures for mold included sputum (2).
Clinical features of endogenous fungal endophthalmitis
| Bilateral | 12/39 (30.8%) | 2/14 (14.3%) | 0.230 |
| Duration of symptoms (mean days ± SD) | 21.0 ± 32.9 | 3.8 ± 5.4 | |
| Hypopyon | 3/50 (6.0%) | 6/16 (37.5%) | |
| Diffuse anterior and posterior inflammation | 33/50 (66.0%) | 11/16 (68.8%) | 0.839 |
| Anterior inflammation only | 2/50 (4.0%) | 1/16 (6.3%) | 0.707 |
| Posterior inflammation only | 15/50 (30.0%) | 4/16 (25.0%) | 0.701 |
SD, standard deviation; Pearson chi-square test used for statistical analysis. Note: Information concerning clinical features was not available for one infant patient with endogenous endophthalmitis caused by yeast.
Initial management strategies for endogenous fungal endophthalmitis
| Local ocular therapy | 41/51 (80.4%) | 13/16 (81.3%) | 0.940 |
| Tap | 12/51 (23.5%) | 5/16 (31.3%) | 0.536 |
| PPV | 29/51 (56.9%) | 8/16 (50.0%) | 0.630 |
| Systemic treatment | 30/51 (58.8%) | 14/16 (87.5%) | |
| Oral | 16/51 (31.4%) | 4/16 (25.0%) | 0.627 |
| Intravenous | 14/51 (27.5%) | 10/16 (62.5%) |
Tap: diagnostic vitreous tap; PPV, pars plana vitrectomy with culture; Pearson chi-square test used for statistical analysis.
Treatment outcomes of endogenous fungal endophthalmitis
| Visual Acuity (VA) | | ||
| Presenting mean | 1.15 (± 0.78) | 1.80 (± 0.80) | |
| logMAR VA (+/− SD) | |||
| Final mean logMAR | 1.05 (± 1.01) | 1.97 (± 1.18) | |
| VA (± SD) | |||
| Change mean | 0.11 (± 0.98) | −0.17 (± 1.24) | 0.384 |
| logMAR VA (± SD) | |||
| Multiple IVF injections | 17/51 (33.3%) | 8/16 (50.0%) | 0.229 |
| Retinal detachment | 15/49 (30.6%) | 2/16 (12.5%) | 0.201 |
| Cataract | 11/49 (22.4%) | 1/16 (6.25%) | 0.147 |
| Enucleation | 0/51 (0.0%) | 4/16 (25.0%) | < 0.001 |
SD, standard deviation; IVF, intravitreal antifungal; Student’s t test used for statistical analysis of presenting, final, and change in VA; Pearson chi-square test used for statistical analysis of retinal detachment, cataract formation, and enucleation rate.